Nykode Therapeutics ASA — Share Issue/Capital Change 2021

May 4, 2021

Grant of share options

Grant of share options

Oslo, Norway, May 3, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced that 800,000 share options have been granted to Harald Gurvin in connection with his appointment as Chief Financial Officer. The share options will have a strike price of NOK 76.77 per share, have a five-year term and will vest equally over a four-year vesting period. After the award of the share options, Harald Gurvin holds a total of 800,000 share options and 0 shares.

Please see further details in attached document.